Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a once-daily oral medication called AP1189, at a dose of 100 mg, compared to a placebo in participants who have respiratory insufficiency expected to be caused by respiratory viral infections such as SARS-CoV-2, Influenza A or B, or RSV. This study is a Phase 2, randomized, double-blind, placebo-controlled trial aiming to include 96 hospitalized participants. The goal is to assess AP1189 as an add-on treatment to the standard care provided for these respiratory infections. Participants will be randomly assigned in equal numbers to receive either AP1189 tablets or matching placebo tablets once daily for 14 days, alongside their standard of care treatment. The study monitors participants during this 14-day treatment period to evaluate treatment outcomes and safety. During the study, participants will be assessed for a composite outcome including death, need for invasive mechanical ventilation or ECMO, cardiovascular organ support, or new renal failure within 28 days. The study includes clinical evaluations, oxygen saturation measurements, and safety monitoring during and after treatment. Overall participation lasts at least 28 days to capture these outcomes and monitor participant health.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of an intravenous human plasma-derived C1 esterase inhibitor C1-INH concentrate in people with congenital C1-INH deficiency who experience acute hereditary angioedema HAE attacks. This phase 3 study compares the C1-INH concentrate to a placebo to treat and prevent acute HAE attacks before procedures. The trial is randomized, double-blind, and involves multiple centers to assess treatment impact on symptom relief. Participants receive either OCTA-C1-INH, a purified human plasma-derived concentrate given as a slow intravenous injection at a dose of 20 IUkg body weight after their first qualifying attack, or a placebo consisting of a sodium chloride injection. The treatment is administered in a blinded manner for some participants, while others receive open-label OCTA-C1-INH. This design aims to measure the treatments ability to relieve symptoms quickly and prevent attacks. During the study, participants are monitored for the time to symptom relief within 4 hours after injection, response rates to treatment, and changes in symptom severity at affected sites. Researchers collect data on the onset of symptom relief and evaluate safety. The study continues until the primary outcome completion date, with participants expected to comply with study procedures and attend scheduled visits for assessment and monitoring.